The need for a therapy to combat the contagious coronavirus disease (COVID-19) has led pharmaceutical companies to fast-track development plans, raising concerns over safety data.
Verdict has conducted a poll to assess the level of confidence in reliability of data regarding COVID-19 therapies.
Go deeper with GlobalData
Analysis of the poll results shows that confidence in reliability of data regarding COVID-19 therapies is moderately high, as voted by 60% of the respondents including 32% who believe that the data has minor issues but is generally reliable and 28% who believe that the data is reliable.
Approximately 20% of the respondents voted that they do not have confidence in the data available, while 20% believed that the data has major issues and is generally unreliable.
The analysis is based on 208 responses received from readers of Pharmaceutical Technology, a Verdict network site, between 27 July and 07 October 2020.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalDataNeed for transparency in development of COVID-19 therapies
More than 150 vaccines for COVID-19 are estimated to be under development across the world. Pharmaceutical companies are running different phases of the trials simultaneously to fast-track the vaccine development which, however, is raising concerns on whether the vaccines will clear safety trials.
Further, political pressure in the development of vaccines is raising doubts that a vaccine may be approved for emergency use without sufficient evidence. In the US, for example, President Donald Trump requested the U.S. Food and Drug Administration (FDA) to aim for a vaccine approval by 01 November.
The FDA agreed to expedite the approval process but released a statement that stringent safety standards will be followed during the same.
Several pharmaceutical companies have stated that they will apply for the approval process only after safety and efficacy of a vaccine is demonstrated in a phase three clinical study. The statement was aimed at increasing public trust in COVID-19 therapies and contains clinical study protocols for their late-stage studies.
